CoChat

Sleep Restriction for 1 Week Reduces Insulin Sensitivity in Healthy Men

Open access

The DOI matches its Crossref record; 56 of the 62 references it cites were found in a registry or an index; 13 of the 57 sources its claims cite were checked for support.

Abstract

OBJECTIVE: Short sleep duration is associated with impaired glucose tolerance and an increased risk of diabetes. The effects of sleep restriction on insulin sensitivity have not been established. This study tests the hypothesis that decreasing nighttime sleep duration reduces insulin sensitivity and assesses the effects of a drug, modafinil, that increases alertness during wakefulness. RESEARCH DESIGN AND METHODS: This 12-day inpatient General Clinical Research Center study included 20 healthy men (age 20–35 years and BMI 20–30 kg/m2). Subjects spent 10 h/night in bed for ≥8 nights including three inpatient nights (sleep-replete condition), followed by 5 h/night in bed for 7 nights (sleep-restricted condition). Subjects received 300 mg/day modafinil or placebo during sleep restriction. Diet and activity were controlled. On the last 2 days of each condition, we assessed glucose metabolism by intravenous glucose tolerance test (IVGTT) and euglycemic-hyperinsulinemic clamp. Salivary cortisol, 24-h urinary catecholamines, and neurobehavioral performance were measured. RESULTS: IVGTT-derived insulin sensitivity was reduced by (means ± SD) 20 ± 24% after sleep restriction (P = 0.001), without significant alterations in the insulin secretory response. Similarly, insulin sensitivity assessed by clamp was reduced by 11 ± 5.5% (P < 0.04) after sleep restriction. Glucose tolerance and the disposition index were reduced by sleep restriction. These outcomes were not affected by modafinil treatment. Changes in insulin sensitivity did not correlate with changes in salivary cortisol (increase of 51 ± 8% with sleep restriction, P < 0.02), urinary catecholamines, or slow wave sleep. CONCLUSIONS: Sleep restriction (5 h/night) for 1 week significantly reduces insulin sensitivity, raising concerns about effects of chronic insufficient sleep on disease processes associated with insulin resistance.

Overview

CoChat Summary

TL;DR

In healthy men, restricting sleep to 5 h/night for 1 week reduced insulin sensitivity by both IVGTT and euglycemic-hyperinsulinemic clamp, without altering insulin secretion. Modafinil improved sleepiness but did not affect glucose metabolism.

Key findings

  • IVGTT-derived insulin sensitivity (SI) fell by 20 ± 24% after sleep restriction (P = 0.001), with 15 of 19 subjects showing a decrease.
  • Clamp-derived insulin sensitivity (M) fell by 11 ± 5.5% after sleep restriction (P < 0.04; results report P = 0.045), and 90% of subjects had a decrease.
  • Glucose tolerance and the disposition index were also reduced by sleep restriction, while the acute insulin response was not significantly affected.
  • Modafinil did not affect any metabolic outcomes, although it reduced subjective and objective sleepiness; cortisol increased with sleep restriction but changes in insulin sensitivity did not correlate with cortisol, urinary catecholamines, or slow-wave sleep.

Methods

  • Double-blind, placebo-controlled, randomized 12-day inpatient General Clinical Research Center study in 20 healthy men (mean ± SD age 26.8 ± 5.2 years; BMI 23.3 ± 3.1 kg/m²; 11 placebo, 9 modafinil).
  • Subjects spent 10 h/night in bed for ≥8 nights including three inpatient baseline nights, then 5 h/night in bed for 7 nights; diet and activity were controlled, and modafinil (300 mg/day) or placebo was given during sleep restriction.
  • Glucose metabolism was assessed on the last 2 days of each condition by insulin-modified frequently sampled IVGTT and euglycemic-hyperinsulinemic clamp; mixed-effects models tested sleep restriction, drug, and interaction effects.

Limitations

  • The paper states a small sample limited to healthy nonobese men and no control group that continued the 10 h/night sleep-replete condition through to study end.
  • The paper notes that controlled food intake may have dampened the full effects of sleep restriction, and circadian phase was not measured directly, though modeling estimated <9 min variation.
  • Evident from the text: three additional subjects withdrew after starting modafinil because of transient EKG changes, tachycardia, and elevated blood pressure, so tolerability and generalizability are further constrained.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2337/db09-0699

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIG. 1. Protocol schema. (See research design and methods for a detailed description.)
FIG. 1. Protocol schema. (See research design and methods for a detailed description.)CC BY-NC-ND · PubMed Central
FIG. 2. Subjective sleepiness and lapses of attention under sleep restriction conditions. Effects of sleep restriction on subjective sleepiness (top panel) and lapses of attention (bottom panel). Subjective sleepiness and objective lapses of attention in sleep-replete subjects were assessed after 10 h of TIB per night and after restricting sleep to 5 h/night over 1 week (days 1–6 averages) in subjects randomized to placebo (red circles) or modafinil administration (green triangles). Subjective sleepiness is defined as mean deviation from baseline Karolinska Sleepiness Scale (KSS). Lapses of attention are defined as reaction times >500 ms and are quantified as the absolute deviation from baseline (lapses/test per day). For self-reported sleepiness, we noted significant main effects of sleep restriction (P < 0.0001), treatment (P < 0.0001), and their interaction (P < 0.0001). With modafinil administration, self-reported sleepiness was significantly reduced compared with placebo after the first and second nights of sleep restriction only (P = 0.0276). For lapses of attention, there was a significant main effect of number of nights of sleep restriction (P = 0.0012) and a borderline effect for treatment (P = 0.0647), and their interaction was nonsignificant (P = 0.1488). With modafinil administration, lapses of attention were significantly reduced compared with placebo during the daytime testing after the first and second nights of sleep restriction only (P = 0.0141); after the second and third nights, the borderline P values were 0.0779 and 0.0770, respectively.
FIG. 2. Subjective sleepiness and lapses of attention under sleep restriction conditions. Effects of sleep restriction on subjective sleepiness (top panel) and lapses of attention (bottom panel). Subjective sleepiness and objective lapses of attention in sleep-replete subjects were assessed after 10 h of TIB per night and after restricting sleep to 5 h/night over 1 week (days 1–6 averages) in subjects randomized to placebo (red circles) or modafinil administration (green triangles). Subjective sleepiness is defined as mean deviation from baseline Karolinska Sleepiness Scale (KSS). Lapses of attention are defined as reaction times >500 ms and are quantified as the absolute deviation from baseline (lapses/test per day). For self-reported sleepiness, we noted significant main effects of sleep restriction (P < 0.0001), treatment (P < 0.0001), and their interaction (P < 0.0001). With modafinil administration, self-reported sleepiness was significantly reduced compared with placebo after the first and second nights of sleep restriction only (P = 0.0276). For lapses of attention, there was a significant main effect of number of nights of sleep restriction (P = 0.0012) and a borderline effect for treatment (P = 0.0647), and their interaction was nonsignificant (P = 0.1488). With modafinil administration, lapses of attention were significantly reduced compared with placebo during the daytime testing after the first and second nights of sleep restriction only (P = 0.0141); after the second and third nights, the borderline P values were 0.0779 and 0.0770, respectively.CC BY-NC-ND · PubMed Central
FIG. 3. Salivary (free) cortisol levels with sleep restriction. Salivary cortisol levels were assessed hourly from 1500 to 2100 h under sleep-replete conditions (10 h/night TIB [black circles]) and under sleep-restricted conditions (5 h/night TIB for 1 week) in subjects receiving placebo (red circles) or modafinil (green triangles). Salivary cortisol levels (means ± SD) from 1500 to 2100 h were significantly affected by sleep duration only: 0.13 ± 0.03 ng/ml for the sleep-replete condition and 0.17 ± 0.04 ng/ml for the sleep-restricted condition (P < 0.0001 and Table 1). Identical (mixed composition) dinners were served just after the 1800-h saliva sample and finished before 1840 h.
FIG. 3. Salivary (free) cortisol levels with sleep restriction. Salivary cortisol levels were assessed hourly from 1500 to 2100 h under sleep-replete conditions (10 h/night TIB [black circles]) and under sleep-restricted conditions (5 h/night TIB for 1 week) in subjects receiving placebo (red circles) or modafinil (green triangles). Salivary cortisol levels (means ± SD) from 1500 to 2100 h were significantly affected by sleep duration only: 0.13 ± 0.03 ng/ml for the sleep-replete condition and 0.17 ± 0.04 ng/ml for the sleep-restricted condition (P < 0.0001 and Table 1). Identical (mixed composition) dinners were served just after the 1800-h saliva sample and finished before 1840 h.CC BY-NC-ND · PubMed Central
FIG. 4. Effects of sleep restriction on glucose metabolism. A and B: Mean glucose levels (± SE) from IVGTT during the baseline sleep-replete condition (10 h/night TIB [black line]) and following sleep restriction for 1 week (5 h/night TIB) in subjects receiving placebo (A) (red line) modafinil (B) (green line). Left arrow, glucose infusion at time = 0 min; right arrow, insulin infusion at time = 20 min. C and D: Mean insulin levels (± SE) from IVGTT. E–H: IVGTT parameters were calculated using Minmod Millennium software. Glucose and insulin data from insulin-modified IVGTT procedures under sleep-replete (filled symbols) and sleep-restricted conditions (open symbols) are shown. E: Acute insulin response (AIRg) (first phase). F: Disposition index. G: SI from IVGTT. H: relative changes in SI from IVGTT expressed as percent change from baseline sleep-replete condition in subjects randomized to placebo (red circles) or modafinil administration (green triangles). I: Insulin sensitivity (M) from euglycemic-hyperinsulinemic clamp procedure. J: Relative changes in insulin sensitivity (M) depicted as in F. There were no significant effects of drug administration on any metabolic parameters (Table 1).
FIG. 4. Effects of sleep restriction on glucose metabolism. A and B: Mean glucose levels (± SE) from IVGTT during the baseline sleep-replete condition (10 h/night TIB [black line]) and following sleep restriction for 1 week (5 h/night TIB) in subjects receiving placebo (A) (red line) modafinil (B) (green line). Left arrow, glucose infusion at time = 0 min; right arrow, insulin infusion at time = 20 min. C and D: Mean insulin levels (± SE) from IVGTT. E–H: IVGTT parameters were calculated using Minmod Millennium software. Glucose and insulin data from insulin-modified IVGTT procedures under sleep-replete (filled symbols) and sleep-restricted conditions (open symbols) are shown. E: Acute insulin response (AIRg) (first phase). F: Disposition index. G: SI from IVGTT. H: relative changes in SI from IVGTT expressed as percent change from baseline sleep-replete condition in subjects randomized to placebo (red circles) or modafinil administration (green triangles). I: Insulin sensitivity (M) from euglycemic-hyperinsulinemic clamp procedure. J: Relative changes in insulin sensitivity (M) depicted as in F. There were no significant effects of drug administration on any metabolic parameters (Table 1).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

9 Valid · 0 Not valid · 22 Not checked · 71 Own results and interpretations

48 more claims

Create a free account to see all 102 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • Probably not a substantial claim. 33
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

17 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 56 references

Research works printed but not linked: 2

  1. Hale, 2007, Does the demography of sleep contribute to health disparities?, 1
  2. Caraway, 1987, Carbohydrates, 422

Cited by

Items 501–598 of 598

Metadata

Authors
Buxton, O. M., Pavlova, M., Reid, E. W., Wang, W., Simonson, D. C., & Adler, G. K.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Buxton, Orfeu M.
Venue
Diabetes
Published
2010-06-28
Volume
59
Issue
9
Pages
2126-2133
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2162026342
Cited by
604
References
62
Citations by year
2026: 25 · 2025: 25 · 2024: 36 · 2023: 34 · 2022: 46 · 2021: 46 · 2020: 41 · 2019: 37 · 2018: 44 · 2017: 33 · 2016: 49 · 2015: 44 · 2014: 35 · 2013: 44 · 2012: 31
FWCI
44.98
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Brigham and Women's Hospital (M01 RR02635)
  • National Institutes of Health (RR‐02635)
  • National Institute on Aging (P01AG009975)
  • National Center for Research Resources (M01RR002635)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
Keywords
sleep restriction, insulin sensitivity, modafinil, glucose tolerance, insulin resistance, insulin secretion, cortisol, catecholamines, slow-wave sleep, disposition index, short sleep duration, healthy men
MeSH terms
Modafinil, Adult, Central Nervous System Stimulants, Attention, Basal Metabolism, Benzhydryl Compounds, Blood Glucose, Calorimetry, Indirect, Double-Blind Method, Glucose Tolerance Test, Humans, Hyperinsulinism, Insulin, Male, Reference Values, Sleep Deprivation, Wakefulness, Glucose Clamp Technique, Patient Selection, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.